eTable 1

	After 2-dose mRNA-1273					After 3-dose mRNA-1273			
	n	Age	Sex	B cell (x10 ⁹ /l) 1	n	Age	Sex	B cell (x10 ⁹ /l) ²	
		mean (SD)	women (%)	median (range)		mean (SD)	women (%)	median (range)	
All patients	161	60.2 (10)	64 (39.8)	0.10 (0.0-86.0)	129	60.1 (10.3)	53 (41.1)	0.11 (0.00-14.95)	
Lymphoma									
During rituximab +/- chemotherapy	2	70 (6)	0 (0)	0.00 (0.00-0.00)	1	74 (0)	0 (0.0)	0.00 (0.00-0.00)	
< 12 months after rituximab +/- chemotherapy	6	60 (15)	2 (33.3)	0.01 (0.00-0.04)	4	61 (17)	2 (50.0)	0.15 (0.00-0.45)	
< 12 months after autologous HCT (BEAM)	7	53 (17)	4 (57.1)	0.12 (0.00-0.19)	5	50 (19)	4 (80.0)	0.22 (0.17-0.23)	
Multiple myeloma									
1st line therapy	7	58 (9)	3 (42.9)	0.03 (0.01-0.04)	2	68 (4)	1 (50.0)	0.04 (0.01-0.08)	
Daratumumab-containing therapy	28	63 (7)	12 (40.0)	0.05 (0.00-0.62)	30	63 (7)	12 (40.0)	0.04 (0.00-0.33)	
IMiDs	15	60 (7)	5 (33.3)	0.10 (0.00-0.27)	14	59 (6)	5 (35.7)	0.09 (0.00-0.25)	
< 9 months after autologous HCT (HDM)	13	62 (7)	4 (30.8)	0.12 (0.01-86)	10	61 (7)	3 (30.0)	0.11 (0.03-0.37)	
Chronic lymphocytic leukemia									
Wait & see	14	63 (9)	6 (42.9)	8.31 (1.10-75.01)	12	62 (9)	5 (41.6)	7.50 (1.25-14.96)	
Ibrutinib	4	58 (6)	2 (50.0)	2.08 (0.02-56.10)	1	54 (0)	1 (100.0)	na	
Chronic myeloid leukemia									
Tyrosine kinase inhibitors	12	52 (10)	5 (41.7)	0.23 (0.14-0.50)	10	52 (10)	3 (30.0)	0.17 (0.08-0.23)	
Acute myeloid leukemia and high-risk MDS									
Hypomethylating therapy	5	59 (22)	1 (20.0)	0.04 (0.00-0.10)	3	52 (29)	1 (33.3)	0.05 (0.00-0.07)	
High-dose chemotherapy	5	64 (2)	3 (60.0)	0.06 (0.01-0.24)	4	64 (2)	3 (75.0)	0.18 (0.06-0.28)	
Myeloproliferative disease									
Ruxolitinib	17	59 (8)	9 (52.9)	0.17 (0.05-0.59)	12	58 (11)	5 (41.6)	0.11 (0.07-0.30)	
Allogeneic HCT									
< 6 months after HCT	12	61 (11)	5 (41.7)	0.01 (0.00-0.28)	9	65 (6)	5 (55.5)	0.19 (0.07-0.49)	
Chronic GvHD	13	61 (10)	3 (23.1)	0.11 (0.00-1.09)	12	60 (10)	3 (25.0)	0.14 (0.00-0.81)	
CAR T cell therapy									
CD19-directed	1	72	0 (0)	0.00 (0.00-0.00)	0	na	na	na	
				•					

Supplemental Table 1: Baseline characteristics of patients included in pseudovirus neutralisation analysis. These were all patients with S1 IgG 50-300 BAU/ML and a random selection of patients with S1 IgG ≥300 BAU/ml after the standard 2-dose mRNA-1273 schedule (Haggenburg ea, Blood Advances 2022). ¹Absolute B cell number at time of inclusion; ²absolute B cell number at time of 3rd vaccination. Na: not applicable.

IgG S1 after 2nd vaccination (BAU/ml)

	N	%	median 25th - 75th perc		h percentile
All patients	104	15.1	2323.0	529.1	5133.5
Lymphoma					
During R-chemo	3	7.0	0.1	0.1	
<12 months after R-chemo	3	7.7	10539.1	2812.7	
<12 months after autologous HCT (BEAM)	3	10.7	7012.2	68.1	
Multiple myeloma					
1st line therapy	2	8.0	38.1	20.5	
Daratumumab-containing therapy	4	8.3	1310.3	291.2	2481.5
IMiDs	8	14.8	1129.0	357.3	16229.4
<9 months after autologous HCT (HDM)	4	8.3	3278.0	1942.2	3402.5
Chronic lymphocytic leukemia					
Wait & see	11	20.4	2934.1	307.4	9315.9
Ibrutinib	3	8.3	748.6	319.7	
Sickle cell disease					
Hydrea containing therapy	31	100.0	2920.8	1760.8	5567.8
Chronic Myeloid leukemia					
Tyrosine kinase inhibitors	10	19.2	2252.5	1447.5	3654.2
Acute myeloid leukemia and high-risk MDS					
Hypomethylating therapy	0	0.0			
High-dose chemotherapie	3	14.3	2842.2	1101.2	
Myeloproliferative disease					
Ruxolitinib	6	16.2	1909.4	614.2	5084.5
Allogenic SCT					
< 6 months after HCT	1	2.0	175.8	175.8	175.8
Chronic GvHD	5	8.9	8964.6	3149.3	17534.5
CAR T cell therapy					
CD19-directed	7	14.0	0.1	0.1	529.1

Supplemental Table 2: Patients who did not receive a 3rd vaccination. From the n=723 patients included in the cohort (Haggenburg ea, Blood Adv 2022), n=104 patients did not receive a 3rd vaccination. Only patients with hematologic malignancies were prioritized per Dutch COVID-19 vaccination protocol, and sickle cell disease patients (n=31) did not receive a 3rd vaccination within the timeframe of current analyses. The other patients (n=71) deferred the 3rd vaccination for personal reasons, most often because they felt they were sufficiently protected or they thought a 3rd vaccination would not be effective anyway. N: number of patients that did not receive a 3rd vaccination during the time under study.

	Baseline, n (%)	Follow up, n (%)
All patients	24 (4.2)	22 (2.0)
Lymphoma		
During rituximab \pm chemotherapy	1 (2.6)	1 (2.5)
<12mo after rituximab \pm chemotherapy	0	1 (2.8)
<12mo after autologous HCT (BEAM)	0	0
Multiple myeloma		
1 st line therapy	1 (4.3)	2 (4.3)
Daratumumab	1 (2.3)	2 (2.3)
IMiDs	5 (10.9)	2 (2.2)
<9mo after autologous HCT (HDM)	5 (11.4)	1 (2.3)
CLL		
Watch & wait	0	3 (2.3)
Ibrutinib	2 (6.1)	1 (3.0)
CML		
Tyrosine kinase inhibitor	2 (4.8)	4 (2.4)
AML and high-risk MDS		
Hypomethylating therapy	0	0
High-dose chemotherapy	0	0
Myeloproliferative disease		
Ruxolitinib	2 (6.5)	0
Allogeneic HCT		
< 6 mo after HCT	1 (2.1)	2 (2.0)
Chronic GvHD	2 (4.3)	2 (2.0)

eTable 3

Supplemental Table SABARS-LOV-2 infected Patients. Indicated are patients who had been SARS-CoV-2 infected prior to vaccination ('baseline') or became infected during follow up. Prior SARS-CoV-2 infection is the first and saline of the sali

SARS-CoV-2 infection

Α

	All	IgG S1 after 2 nd vaccination (BAU/ml)			Time (days)¹	Time (days) ¹ IgG S1 after 3 rd vaccination (BAU/ml				p-value	
	<u>N</u>	N	median	25th - 75th	percentile	Median (range)	N	median	25th - 75th	percentile	3 rd vs 2 nd
All patients	27	25	443.1	31.4	3872.6	88 (1-140)	26	540.8	60.0	8819.0	0.19
Autologous HCT											
BEAM	2	2	0.1	0.1		33 (1-64)	2	59.5	1.4		0.18
HDM	14	13	562.6	130.8	3872.6	102 (30-140)	13	8498.5	1315.4	12576.3	0.02
Bu/Cy	1	1	139.5	139.5	139.5	103	1	11767.1	11767.1	11767.1	-
Allogenic HCT ²	7	6	832.4	144.0	6379.8	65 (41-106)	7	73.5	49.0	109.2	0.05
CAR T cell therapy	3	3	0.1	0.1		92 (43-119)	3	0.3	0.1		0.65

B

	N	%	Autologous HCT	Allogeneic HCT	CAR T cell
All patients	27	4.6	17	7	3
Lymphoma					
During R-chemo	3	7.5	1	-	2
<12 months after R-chemo	1	2.8	1	-	-
<12 months after autologous HCT (BEAM)	1	4.0	-	-	1
Multiple myeloma					
1st line therapy	14	60.9	14	-	-
Chronic lymphocytic leukemia					
Ibrutinib	1	3.0	-	1	-
Acute myeloid leukemia and high-risk MDS					
Hypomethylating therapy	3	18.8	-	3	-
High-dose chemotherapie	4	22.2	1	3	-

Supplemental Table 4: Characteristics of patients who received cell therapy after the 2nd mRNA-**1273 vaccination. A.** Types of cell therapy received. ¹Time between cell therapy and 3rd vaccination. ²All allogeneic HCT recipients received lymphocyte replete transplants with a haploidentical donor (n=3; 2 unvaccinated donors, 1 vaccinated), matched unrelated donor (n=3; vaccination status unknown) or cord blood donor (n=1). Six had GvHD prophylaxis (n=2) or GvHD therapy (n=4) at the time of 3rd vaccination, which consisted of a calcineurin inhibitor or sirolimus, mycophenolic acid and/or prednisolone. BEAM: carmustine, etoposide, cytarabine, melphalan; HDM: high dose melphalan; Bu/Cy; busulphan cyclophosphamide. B. Cohorts of which intercurrent cell therapy patients were from.